Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence

J Consult Clin Psychol. 2014 Dec;82(6):964-72. doi: 10.1037/a0037496. Epub 2014 Aug 4.

Abstract

Objective: To examine the benefit of adding an Internet-delivered behavior therapy to a buprenorphine medication program and voucher-based motivational incentives.

Method: A block-randomized, unblinded, parallel, 12-week treatment trial was conducted with 170 opioid-dependent adult patients (mean age = 34.3 years; 54.1% male; 95.3% White). Participants received an Internet-based community reinforcement approach intervention plus contingency management (CRA+) and buprenorphine or contingency management alone (CM-alone) plus buprenorphine. The primary outcomes, measured over the course of treatment, were longest continuous abstinence, total abstinence, and days retained in treatment.

Results: Compared to those receiving CM-alone, CRA+ recipients exhibited, on average, 9.7 total days more of abstinence (95% confidence interval [CI = 2.3, 17.2]) and had a reduced hazard of dropping out of treatment (hazard ratio = 0.47; 95% CI [0.26, 0.85]). Prior treatment for opioid dependence significantly moderated the additional improvement of CRA+ for longest continuous days of abstinence.

Conclusions: These results provide further evidence that an Internet-based CRA+ treatment is efficacious and adds clinical benefits to a contingency management/medication based program for opioid dependence.

Trial registration: ClinicalTrials.gov NCT00929253.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Analgesics, Opioid / administration & dosage
  • Buprenorphine / administration & dosage
  • Cognitive Behavioral Therapy / methods*
  • Combined Modality Therapy
  • Female
  • Humans
  • Internet*
  • Male
  • Middle Aged
  • Motivation*
  • Narcotic Antagonists / administration & dosage
  • Opiate Substitution Treatment* / methods
  • Opioid-Related Disorders / drug therapy
  • Opioid-Related Disorders / therapy*
  • Reinforcement, Psychology*
  • Residence Characteristics
  • Treatment Outcome

Substances

  • Analgesics, Opioid
  • Narcotic Antagonists
  • Buprenorphine

Associated data

  • ClinicalTrials.gov/NCT00929253